AG Mednet announces leadership changes amid Judi platform growth in Boston

AG Mednet, a leader in clinical trial process management, has announced significant leadership changes in response to the rapid growth of its Judi platform, which is now utilized in over 2,000 clinical trials globally. The company has appointed Catherine Tyner as Head of Clinical Strategy and Jamie Russo as Head of Product, both of whom bring extensive experience in clinical research and product management. Tyner's background includes oversight of over 500 clinical trials, while Russo has a strong foundation in healthcare technology and clinical operations. The Judi platform has gained traction among more than 640 drug and device sponsors and 90 Contract Research Organizations (CROs), highlighting its effectiveness in streamlining clinical trial processes. The platform is recognized for enhancing collaboration, improving efficiencies, and simplifying critical aspects of clinical trial conduct, such as centralized eligibility determination and medical imaging. The appointments of Tyner and Russo are strategic moves aimed at maintaining AG Mednet's commitment to innovation and client satisfaction amid unprecedented demand for the Judi platform. Their combined expertise is expected to drive further advancements in clinical process management, ensuring that AG Mednet remains at the forefront of the industry. With over 100 unique trial sponsors adopting the Judi ecosystem in the past year, AG Mednet is solidifying its position as a key player in the clinical trial landscape. The company’s focus on optimizing workflows and facilitating communication is crucial for accelerating the development of life-saving therapies, reinforcing its role as a vital partner in clinical research.